tiprankstipranks
Ultragenyx Pharmaceutical (CH:UP0)
:UP0
Switzerland Market

Ultragenyx Pharmaceutical (UP0) Blogger Opinions & Sentiment

0 Followers

Blogger Sentiment

Bullish: 66.00%
Sector Average
Bullish
CH:UP0 Blogger sentiment is based on 6 Blogger Opinions. The Blogger sentiment is more Bullish than other stocks in the Healthcare sector.

Blogger Article Distribution

ArticleDistribution
50% SeekingAlpha
16% Zacks
16% Investing
18% Others
The distribution of articles among the main online Financial Blogging platforms.

Top Blogger Bearish Predictions

Ultragenyx: Why I'm Selling The Osteogenesis Imperfecta Dip
SeekingAlpha
Recent negative articles by top bloggers.

Top Blogger Bullish Predictions

Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
SeekingAlpha
Ultragenyx (RARE) Sees Potential Rebound Despite Recent Setback
GuruFocus
Recent positive articles by top bloggers.

Financial Blogger Predictions​​

Blogger Performance
Any
Any
Blogger Sentiment
Any
Any

FAQ

What do Seeking Alpha bloggers think of CH:UP0?
Seeking Alpha’s Four Gate Alpha has a Bullish Sentiment.
    What do Motley Fool contributors think of CH:UP0?
    Currently there's no blogger sentiment for CH:UP0.
    What Is CH:UP0’s Blogger Sentiment?
    CH:UP0’s Blogger Sentiment is Bullish.
      What was the most recent blogger prediction for CH:UP0?
      The most recent blogger prediction for CH:UP0 was made by Zacks Equity Research, who was Neutral on the stock.
        How can I follow the stock ratings of top Top Financial Bloggers?
        Head over to our Expert Center to see a list of the Top 100 Financial Bloggers and follow the financial bloggers of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Stocks with the Highest Top Blogger Ratings in the Healthcare sector
          CADLCandel Therapeutics
          VERAVera Therapeutics
          MLTXMoonLake Immunotherapeutics
          GTBIFGreen Thumb Industries
          DFTXDefinium Therapeutics